J INTS BIO Presents Interim Results from the Preclinical Study of ‘JIN-001’ in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance

Posted on by

SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ — J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium held in Barcelona, Spain, from October 23-25,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.